late Herceptin thoughts
The more I think of the 50% increase in DFS in the HERA study group, the more I want Herceptin, even if it is late in starting. This is particularly true with the lower response to Herceptin in the metastatic setting. I hope my oncol. will consent to it when I see him next week. I will let you folks know. I am also anxious to see if they address late Herceptin at the San Anton. breast conference. Well, we'll see.
Robin P.
|